Cavitwin Injection No. 1

Adult administration

As a total amino acid, the maximum dosage is 1–1.5 g per kg of body weight per day, and the infusion rate should not exceed 1.0 mL/kg per hour (equivalent to 0.25 g/kg of glucose, 0.05 g/kg of amino acids). Infusing over 12-24 hours is preferable, and this medication should be administered via central venous access as a principle.

Child administration

In children, the dosage and infusion rate should be appropriately adjusted.

This medication must be used strictly according to the physician's instructions, and should not be administered simultaneously with calcium-containing intravenous preparations and ceftriaxone due to potential precipitation. It should not be used in patients with allergic reactions or specific electrolyte imbalances, renal and liver dysfunction, certain heart diseases, and infants under 2 years old. It should be administered with caution to patients with unstable health conditions such as bacteremia, liver failure, kidney failure, and heart failure, as there is a possibility of allergic reactions or asthma attacks due to sodium bisulfite. During administration, blood glucose, electrolytes, liver and kidney functions should be regularly monitored to detect adverse reactions early and respond appropriately. In case of overdose, symptoms such as acidosis, fluid overload, electrolyte imbalance, and hyperglycemia may occur, so the infusion rate and dosage must be strictly managed. The safety of this medication has not been established for pregnant or breastfeeding women, so it should only be administered if the therapeutic benefits outweigh the risks. Elderly patients may have reduced physiological functions, so caution is needed to administer it slowly and adjust the dosage accordingly. This medication should be administered slowly via central venous access, and peripheral venous injection should be avoided. Maintain aseptic conditions during administration, and do not use if there is discoloration of the solution, leakage, or damage to the packaging.

Serious side effects

Hives, severe swelling (peripheral edema), chest tightness, difficulty breathing, respiratory distress, respiratory arrest, shock, bronchospasm, yellowing of the skin or eyes (jaundice), profound general malaise, liver function abnormalities, sudden and severe headache, confusion, vision disturbances, paralysis, severe edema accompanied by increased blood pressure, significantly decreased urine output (oliguria, anuria).

Mild side effects

• Nausea
• vomiting
• chills
• fever
• headache
• chest discomfort
• palpitations
• tachycardia
• increased blood pressure
• hypophosphatemia

This medication should be stored in a sealed container at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness.

Appearance

A pale yellow transparent liquid filled in a transparent plastic container that is divided internally by partitions.

Package unit

1000mL